Concurrent mutations in TP53 and ATRX have been frequently observed in gliomas and sarcomas, with several studies suggesting the combination of these mutations as prognostic indicators associated with poorer survival outcomes [73,74]. The gene discussed is TP53; the disease is central nervous system cancer.